Publication:
Upfront frameless hypofractionated gamma knife radiosurgery for large posterior Fossa metastases

Thumbnail Image

Departments

School / College / Institute

Organizational Unit
SCHOOL OF MEDICINE
Upper Org Unit
Organizational Unit

Program

KU Authors

Co-Authors

Publication Date

Language

Embargo Status

No

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

The management of large metastatic brain tumors (METs), particularly those in the posterior fossa (pf-METs), is challenging. While surgery can alleviate symptoms, it carries the risk of complications such as leptomeningeal disease (LMD). Upfront hypofractionated Gamma Knife radiosurgery (hf-GKRS) has shown promise as an alternative approach for managing large METs. This study assesses the efficacy and safety of upfront hf-GKRS for treatment-na & iuml;ve large pf-METs. In this retrospective, single-center study, 40 patients with 42 pf-METs received hf-GKRS from October 2017 to June 2024. Patients eligible for the study were 18 years or older, had histologically confirmed malignancy, large pf-METs (> 4 cm(3)), and a minimum of two follow-up MRI scans. The primary outcome was local control (LC), with secondary assessments of distant intracranial failure (DICF), intracranial progression-free survival (PFS), overall survival (OS), and toxicity. LC was achieved in 88.1% of pf-METs over a median follow-up of 6 months (mean: 13.7 months). LC rates at 6, 12, and 24 months were 95.8%, 95.8%, and 74.5%, respectively. Local failure (LF) occurred in 11.9% of cases, with a median recurrence time of 12 months. DICF was noted in 35% of patients, while no cases of LMD were reported. Intracranial PFS rates at 6, 12, and 24 months were 54.1%, 39.0%, and 16.7%, respectively, with a median PFS of 8 months. Symptomatic hydrocephalus developed in one patient (2.5%). Controlled primary tumor status (HR: 0.17, p = 0.036) was significantly associated with lower risk of death, while no other parameters were predictive of LC, DICF, or intracranial PFS. hf-GKRS demonstrates strong efficacy and safety as a primary treatment for selected, treatment-na & iuml;ve large pf-METs over a relatively short follow-up duration. Further studies are warranted to refine patient selection, fractionation, and dosing strategies for this challenging population.

Source

Publisher

Springer

Subject

Clinical neurology, Surgery

Citation

Has Part

Source

Neurosurgical Review

Book Series Title

Edition

DOI

10.1007/s10143-025-03572-4

item.page.datauri

Link

Rights

CC BY (Attribution)

Copyrights Note

Creative Commons license

Except where otherwised noted, this item's license is described as CC BY (Attribution)

Endorsement

Review

Supplemented By

Referenced By

0

Views

1

Downloads

View PlumX Details